CN113727729A - 用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法 - Google Patents

用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法 Download PDF

Info

Publication number
CN113727729A
CN113727729A CN202080015963.2A CN202080015963A CN113727729A CN 113727729 A CN113727729 A CN 113727729A CN 202080015963 A CN202080015963 A CN 202080015963A CN 113727729 A CN113727729 A CN 113727729A
Authority
CN
China
Prior art keywords
dexamethasone
daratumab
lenalidomide
multiple myeloma
darunavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080015963.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN113727729A publication Critical patent/CN113727729A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202080015963.2A 2019-02-22 2020-02-21 用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法 Pending CN113727729A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962809070P 2019-02-22 2019-02-22
US62/809070 2019-02-22
US201962829814P 2019-04-05 2019-04-05
US201962829791P 2019-04-05 2019-04-05
US201962829804P 2019-04-05 2019-04-05
US62/829791 2019-04-05
US62/829814 2019-04-05
US62/829804 2019-04-05
PCT/IB2020/051484 WO2020170211A1 (en) 2019-02-22 2020-02-21 Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone

Publications (1)

Publication Number Publication Date
CN113727729A true CN113727729A (zh) 2021-11-30

Family

ID=72141407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080015963.2A Pending CN113727729A (zh) 2019-02-22 2020-02-21 用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法

Country Status (6)

Country Link
US (1) US20200268847A1 (https=)
EP (1) EP3927376A4 (https=)
JP (2) JP7721445B2 (https=)
CN (1) CN113727729A (https=)
CA (1) CA3131064A1 (https=)
WO (1) WO2020170211A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604750A (zh) * 2014-06-16 2017-04-26 梅约医学教育与研究基金会 治疗骨髓瘤
US20170320961A1 (en) * 2014-02-28 2017-11-09 Janssen Biotech, Inc. Anti-CD38 Antibodies for Treatment of Acute Lymphoblastic Leukemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170320961A1 (en) * 2014-02-28 2017-11-09 Janssen Biotech, Inc. Anti-CD38 Antibodies for Treatment of Acute Lymphoblastic Leukemia
CN106604750A (zh) * 2014-06-16 2017-04-26 梅约医学教育与研究基金会 治疗骨髓瘤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
""HIGHLIGHTS OF PRESCRIBING INFORMATION"", pages 3 - 6, Retrieved from the Internet <URL:http://www.fda.gov/drugs/resources-information-approved-drugs/daratumumab-darzalex> *
吴婷 等: ""Daratumumab靶向治疗多发性骨髓瘤的研究进展"", 《生命科学研究》, vol. 21, no. 4, 31 August 2017 (2017-08-31), pages 349 - 354 *

Also Published As

Publication number Publication date
JP2025102775A (ja) 2025-07-08
JP2022523372A (ja) 2022-04-22
CA3131064A1 (en) 2020-08-27
JP7721445B2 (ja) 2025-08-12
EP3927376A4 (en) 2022-11-09
EP3927376A1 (en) 2021-12-29
WO2020170211A1 (en) 2020-08-27
US20200268847A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
CN113727729A (zh) 用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法
US20220204638A1 (en) Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200397896A1 (en) Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200405854A1 (en) Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200308297A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
JP2022512722A (ja) 抗ｃｄ３８抗体の皮下投与を提供する方法
JP2025148430A (ja) 多発性骨髄腫の処置方法
AU2021391623A9 (en) Anti-cd19 combination therapy
US20220275101A1 (en) Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
JP2022532356A (ja) 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法
TW202525850A (zh) 治療慢性發炎性脫髓鞘多發性神經病變之方法
TW202432135A (zh) 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－氧雜環丁－３－基）哌𠯤－１－基］戊－２－烯腈治療免疫性血小板減少症的方法
US20200330594A1 (en) Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20240368310A1 (en) Use of approved bispecific egfr and met specific antibody drug product to treat non-small cell lung cancer
US20230233676A1 (en) Use of Approved Anti-CD38 Antibody Drug Product in Combination with Pomalidomide and Dexamethasone to Treat Multiple Myeloma
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
TWI870415B (zh) 使用抗cd38抗體之組合療法
WO2020212914A1 (en) Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
US20240270838A1 (en) Method for prophylactic therapy of cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome (icans)
WO2020212911A2 (en) Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
HK40121853A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤
JP2026512040A (ja) 投薬レジメン
AU2025316407A1 (en) Daratumumab.bortezomib, lenalidomide and dexamethasone for treating multiple myeloma
NOC This product has been authorized under the Notice of Compliance with Conditions (NOC/c) for one or all of its indicated uses.
Manual Immune Globulin, Autoimmune, Rheumatic and Neurologic Indications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination